The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines
Authors:
- 18 April 2009
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 32 (3) , 424-440
Abstract
Summary: Fabry disease is an X‐linked lysosomal storage disorder caused by mutations in the gene encoding α‐galactosidase A (α‐Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL‐3). Over 500 Fabry mutations have been reported; approximately 60% are missense. The iminosugar 1‐deoxygalactonojirimycin (DGJ, migalastat hydrochloride, AT1001) is a pharmacological chaperone that selectively binds α‐Gal A, increasing physical stability, lysosomal trafficking, and cellular activity. To identify DGJ‐responsive mutant forms of α‐Gal A, the effect of DGJ incubation on α‐Gal A levels was assessed in cultured lymphoblasts from males with Fabry disease representing 75 different missense mutations, one insertion, and one splice‐site mutation. Baseline α‐Gal A levels ranged from 0 to 52% of normal. Increases in α‐Gal A levels (1.5‐ to 28‐fold) after continuous DGJ incubation for 5 days were seen for 49 different missense mutant forms with varying EC50 values (820 nmol/L to >1 mmol/L). Amino acid substitutions in responsive forms were located throughout both structural domains of the enzyme. Half of the missense mutant forms associated with classic (early‐onset) Fabry disease and a majority (90%) associated with later‐onset Fabry disease were responsive. In cultured fibroblasts from males with Fabry disease, the responses to DGJ were comparable to those of lymphoblasts with the same mutation. Importantly, elevated GL‐3 levels in responsive Fabry fibroblasts were reduced after DGJ incubation, indicating that increased mutant α‐Gal A levels can reduce accumulated substrate. These data indicate that DGJ merits further evaluation as a treatment for patients with Fabry disease with various missense mutations.Keywords
This publication has 37 references indexed in Scilit:
- Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperonePharmacogenetics and Genomics, 2008
- Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycinBiochemical Journal, 2007
- Screening for pharmacological chaperones in Fabry diseaseBiochemical and Biophysical Research Communications, 2007
- Structure–function relationships in α‐galactosidase AActa Paediatrica, 2007
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006
- Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypesHuman Genetics, 2005
- Human Gene Mutation Database (HGMD®): 2003 updateHuman Mutation, 2003
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997
- Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic ReticulumBiochemical and Biophysical Research Communications, 1996
- Galactose Stabilizes Various Missense Mutants of α-Galactosidase in Fabry DiseaseBiochemical and Biophysical Research Communications, 1995